Clinical Trials Directory

Trials / Completed

CompletedNCT05927285

Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
140 (actual)
Sponsor
Hospital Civil de Guadalajara · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

During cardiorenal syndrome type 1 (CRS1) vascular congestion is the major contributor to worsening renal function, but promoting decongestion with routine clinical evaluation is ineffective in some patients. The venous evaluation by ultrasound (VExUS) may optimize its management when evaluating for improvement in kidney function and other metrics related to decongestion.

Detailed description

Background: In cardiorenal syndrome type 1 (CRS1) vascular congestion is a common complication, the Venus Evaluation by Ultrasound System (VExUS) could guide decongestion effectively and thereby improve kidney function outcomes. Methods: In this double-blind randomized clinical trial, patients with CRS1 were randomized to guide decongestion with VExUS compared to usual clinical evaluation. The primary and secondary endpoint was to assess kidney function recovery (KFR), days of hospitalization, mortality, changes in brain natriuretic peptide (BNP) and CA-125. Protocol register HCG/CEI-0836/22.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTVexusThe VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
OTHERControl groupThe control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested

Timeline

Start date
2022-03-20
Primary completion
2023-02-20
Completion
2023-02-26
First posted
2023-07-03
Last updated
2023-07-10

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT05927285. Inclusion in this directory is not an endorsement.